Carl J Höijer1, Carl Meurling, Johan Brandt. 1. Department of Cardiology, Heart and Lung Division, Lund University Hospital, S-221 85 Lund, Sweden. carl-johan.hoijer@skane.se
Abstract
AIMS: To investigate whether patients with previously implanted conventional pacemakers and severe heart failure benefit from an upgrade to a biventricular system. METHODS AND RESULTS: Study inclusion criteria were New York Heart Association (NYHA) classes III and IV, dominant paced rhythm, and no left bundle branch block in the pre-pacing ECG. Ten patients with pacemakers (four VVIR due to slow atrial fibrillation and six DDDR, of which four were due to high-degree atrioventricular block and two to sinus node disease) were upgraded to a biventricular pacing (BVP) system. The median duration of pacing before the upgrade was 5.7 years. Assessments of 6-min walk test, symptom score, brain natriuretic peptide (pro-BNP), and echocardiography were made pre-operatively. After a run-in period of 1 month in BVP following the upgrade, the patients were randomized to a 2-month period in either BVP or right ventricular pacing (RVP), followed by 2 months in the other mode, in a double-blind crossover fashion. After each period, the pre-operative measurements were repeated. After study completion, patients were asked to select their preferred period. The median 6-min walking distance was significantly longer in BVP (400 m) vs. RVP (315 m), P = 0.02. The symptom score was also significantly better in BVP (P = 0.005). Median pro-BNP was significantly lower in BVP than in RVP, 3,030 vs. 5,064 ng/L (P = 0.005). Six patients demanded an early crossover in RVP but none in BVP (P = 0.015), and all patients except one expressed a preference for BVP. However, echo parameters did not show any significant differences between BVP and RVP. CONCLUSION:Pacemaker patients with heart failure and dominant paced heart rhythm benefit substantially from an upgrade toBVP, in terms of physical performance and symptoms. The upgrade resulted in significantly improved cardiac function as reflected by reduced levels of pro-BNP.
RCT Entities:
AIMS: To investigate whether patients with previously implanted conventional pacemakers and severe heart failure benefit from an upgrade to a biventricular system. METHODS AND RESULTS: Study inclusion criteria were New York Heart Association (NYHA) classes III and IV, dominant paced rhythm, and no left bundle branch block in the pre-pacing ECG. Ten patients with pacemakers (four VVIR due to slow atrial fibrillation and six DDDR, of which four were due to high-degree atrioventricular block and two to sinus node disease) were upgraded to a biventricular pacing (BVP) system. The median duration of pacing before the upgrade was 5.7 years. Assessments of 6-min walk test, symptom score, brain natriuretic peptide (pro-BNP), and echocardiography were made pre-operatively. After a run-in period of 1 month in BVP following the upgrade, the patients were randomized to a 2-month period in either BVP or right ventricular pacing (RVP), followed by 2 months in the other mode, in a double-blind crossover fashion. After each period, the pre-operative measurements were repeated. After study completion, patients were asked to select their preferred period. The median 6-min walking distance was significantly longer in BVP (400 m) vs. RVP (315 m), P = 0.02. The symptom score was also significantly better in BVP (P = 0.005). Median pro-BNP was significantly lower in BVP than in RVP, 3,030 vs. 5,064 ng/L (P = 0.005). Six patients demanded an early crossover in RVP but none in BVP (P = 0.015), and all patients except one expressed a preference for BVP. However, echo parameters did not show any significant differences between BVP and RVP. CONCLUSION: Pacemaker patients with heart failure and dominant paced heart rhythm benefit substantially from an upgrade to BVP, in terms of physical performance and symptoms. The upgrade resulted in significantly improved cardiac function as reflected by reduced levels of pro-BNP.
Authors: Roberto Márcio de Oliveira Júnior; Kátia Regina da Silva; Tatiana Satie Kawauchi; Lucas Bassolli de Oliveira Alves; Elizabeth Sartori Crevelari; Martino Martinelli Filho; Roberto Costa Journal: Arq Bras Cardiol Date: 2014-11-11 Impact factor: 2.000
Authors: Annamaria Kosztin; Mate Vamos; Daniel Aradi; Walter Richard Schwertner; Attila Kovacs; Klaudia Vivien Nagy; Endre Zima; Laszlo Geller; Gabor Zoltan Duray; Valentina Kutyifa; Bela Merkely Journal: Heart Fail Rev Date: 2018-01 Impact factor: 4.214
Authors: Giuseppe Pio Piemontese; Matteo Ziacchi; Giovanni Statuto; Andrea Angeletti; Giulia Massaro; Lorenzo Bartoli; Mauro Biffi Journal: Ann Noninvasive Electrocardiol Date: 2022-03-02 Impact factor: 1.485